Literature DB >> 3324962

Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats.

R Roosendaal1, I A Bakker-Woudenberg, M van den Berghe-van Raffe, J C Vink-van den Berg, M F Michel.   

Abstract

The antibacterial activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in vivo were compared. Although there was only a minor difference between the MBCs of both drugs, the bacterial killing rate of ciprofloxacin in vitro was very fast in comparison with that of ceftazidime. Similarly, the intravenous administration of ciprofloxacin at 1 h after bacterial inoculation resulted in effective bacterial killing in the lungs of leukopenic rats. This killing was dose dependent, in contrast to the dose-independent bactericidal effect of ceftazidime. The high antibacterial activity of ciprofloxacin in the lungs as compared with that of ceftazidime was also reflected in its therapeutic efficacy in K. pneumoniae pneumonia and septicemia in leukopenic rats when these infections were treated at 6-h intervals over 4 days, starting at 5 h after bacterial inoculation. Concentrations of ciprofloxacin and ceftazidime in lung tissue were not significantly different. Regarding the antibacterial activity of both drugs against K. pneumoniae in relation to the bacterial growth rate in vitro and in the lungs of leukopenic rats, ciprofloxacin killed K. pneumoniae organisms that were not actively growing, whereas ceftazidime did not. In addition, it was demonstrated that when the intravenous administration of antibiotic was delayed from 1 h up to 24 h after bacterial inoculation, ceftazidime lost its antibacterial activity in the lungs and blood of leukopenic rats, whereas ciprofloxacin was still very effective. These data suggest that the capacity of an antibiotic to kill bacteria at a slow growth rate may be relevant for its therapeutic effect in established infections, in which slowly growing bacteria form a substantial part of the total bacterial population.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3324962      PMCID: PMC175044          DOI: 10.1128/AAC.31.11.1809

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Penetration of ciprofloxacin into human lung tissue following intravenous injection.

Authors:  D Schlenkhoff; A Dalhoff; J Knopf; W Opferkuch
Journal:  Infection       Date:  1986 Nov-Dec       Impact factor: 3.553

2.  Generation times of Proteus mirabilis and Escherichia coli in experimental infections.

Authors:  W W Eudy; S E Burrous
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

3.  Simplified, accurate method for antibiotic assay of clinical specimens.

Authors:  J V Bennett; J L Brodie; E J Benner; W M Kirby
Journal:  Appl Microbiol       Date:  1966-03

4.  Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia.

Authors:  B S Kramer; P A Pizzo; K J Robichaud; F Witesbsky; R Wesley
Journal:  Am J Med       Date:  1982-04       Impact factor: 4.965

5.  Pharmacokinetics of intravenously administered ciprofloxacin.

Authors:  R Wise; R M Lockley; M Webberly; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

6.  Single versus combination antibiotic therapy for pneumonia due to Pseudomonas aeruginosa in neutropenic guinea pigs.

Authors:  M G Rusnak; T A Drake; C J Hackbarth; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

7.  Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

Authors:  J B Schiff; G J Small; J E Pennington
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy.

Authors:  J P Sculier; D Weerts; J Klastersky
Journal:  Eur J Cancer Clin Oncol       Date:  1984-01

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  15 in total

1.  Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin.

Authors:  Alison K Meagher; Alan Forrest; Axel Dalhoff; Heino Stass; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 2.  Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models.

Authors:  A Dalhoff; U Ullmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; S Kunz; O Zak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 5.  Significance of tissue levels for prediction of antibiotic efficacy and determination of dosage.

Authors:  C Carbon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 6.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

7.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.

Authors:  Aline Vidal Lacerda Gontijo; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

8.  Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic rats.

Authors:  R Roosendaal; I A Bakker-Woudenberg; M van den Berghe-van Raffe; J C Vink-van den Berg; B M Michel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 9.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

10.  Comparative efficacies of ciprofloxacin, amoxicillin, amoxicillin-clavulanic acid, and cefaclor against experimental Streptococcus pneumoniae respiratory infections in mice.

Authors:  J Gisby; B J Wightman; A S Beale
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.